An Adaptive Clinical Trial of Antivirals for COVID-19 Infection
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a randomised placebo controlled phase II trial to examine the efficacy of antivirals
to treat COVID-19 infection compared to placebo for virological cure and improved clinical
outcomes. Individuals will be randomised to the candidate antiviral which in the first
instance is Favipiravir or matched placebo and randomisation will be stratified according to
whether the participant requires hospitalisation or not. This treatment will be given in
addition to the usual standard of care in the participating hospital.